Concepedia

Author

Josep Marés

GlaxoSmithKline (Belgium)

Also Known As

Josep Mares, Josep Marès, Josep Marés

6

Publications

227

Citations

6

H-Index

22

Concepts

All Affiliations

GlaxoSmithKline (Belgium)GlaxoSmithKline (Spain)Centro de Investigación Biomédica en Red de Epidemiología y Salud PúblicaDepartamento de SaludHospital Casa de Salud
JM

About

Josep Marés is an author at GlaxoSmithKline (Belgium) specializing in medicine, vaccination, and immunodominance.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

125

2

Immunology

2

2

53

3

Microbiology

1

1

72

4

Bacterial Pathogens

1

1

72

5

Clinical Microbiology

1

1

72

Josep Marés

×

5

Publications

218

Citations

5

H-Index

YearCitations

Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-Adjuvanted Prepandemic Candidate Influenza Vaccines in Children Aged 3 to 9 Years

Javier Díez‐Domingo, María Garcés‐Sánchez, José‐María Baldó,

The Pediatric Infectious Disease Journal

2010

75

Microbiology of bacteria causing recurrent acute otitis media (AOM) and AOM treatment failure in young children in Spain: Shifting pathogens in the post-pneumococcal conjugate vaccination era

Félix Pumarola, Josep Marés, Isabel Losada,

International Journal of Pediatric Otorhinolaryngology

2013

72

Immunogenicity and Reactogenicity of a Three-Dose Primary Vaccination Course With a Combined Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Inactivated Polio-Haemophilus influenzae Type b Vaccine Coadministered With a Meningococcal C Conjugate Vaccine

Juan Carlos Tejedor Torres, Félix Omeñaca, José García-Sicilia,

The Pediatric Infectious Disease Journal

2004

41

Phase <scp>II</scp>, randomized, open, controlled study of <scp>AS</scp>03‐adjuvanted H5N1 pre‐pandemic influenza vaccine in children aged 3 to 9 years: follow‐up of safety and immunogenicity persistence at 24 months post‐vaccination

Javier Díez‐Domingo, José‐María Baldó, Maria Victoria Planelles‐Catarino,

Influenza and Other Respiratory Viruses

2015

18

Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1–11 years

Helen Marshall, Terry Nolan, Javier Díez‐Domingo,

Vaccine

2010

12

Page 1